Jazz Hits Roxane With Patent Suit Over Xyrem

Law360, New York (May 4, 2011, 4:11 PM EDT) -- Jazz Pharmaceuticals Inc. slapped a Boehringer Ingelheim Corp. subsidiary with another patent infringement suit Monday in New Jersey over its bid for approval to market a generic version of Jazz's narcolepsy treatment Xyrem.

Roxane Laboratories Inc. infringed the lone patent-in-suit when it submitted an application to the U.S. Food and Drug Administration seeking a green light to make, sell or import generic Xyrem, the complaint says. Jazz already has litigation pending against Roxane over Xyrem in the same court over different patents.

Jazz filed suit to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.